AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
May 01, 2018- Application supported by four pivotal Phase 3 trials evaluating more than 2,000 patients with moderate to severe plaque psoriasis (1-3)
-
April 27, 2018- Seven presentations of elagolix data highlight AbbVie's research in endometriosis and uterine fibroids
-
April 26, 2018- Reports First-Quarter Diluted EPS of $1.74 on a GAAP Basis; Adjusted Diluted EPS of $1.87 Reflects Growth of 46.1 Percent
-
April 25, 2018- In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1)
-
April 25, 2018- In SELECT-SUNRISE, upadacitinib met the primary endpoint of ACR20 across all doses (7.5 mg, 15 mg, 30 mg, once-daily) at week 12, with a significant difference in ACR20 compared to placebo observed as early as week one(1)
-
April 10, 2018- FDA requires extended time for review of additional information in New Drug Application (NDA)
-
April 09, 2018- In SELECT-COMPARE, upadacitinib (15 mg, once-daily) met both primary endpoints, with 71 percent of patients achieving ACR20 and 29 percent achieving clinical remission at week 12 (1)
-
April 06, 2018
-
April 05, 2018- Agreements Provide Non-Exclusive License to Samsung Bioepis for HUMIRA-Related Intellectual Property in the U.S. Effective June 30, 2023, and in Other Markets on Different Dates
-
March 22, 2018- AbbVie will not seek accelerated approval for Rova-T in third-line relapsed/refractory small cell lung cancer (SCLC)
-
March 21, 2018- Study is among the largest and most comprehensive in multiple myeloma (MM), and will assess outcomes from 1,500 patients with MM and the t(11;14) translocation at participating International Myeloma Foundation sites globally
-
March 13, 2018− Second of two pivotal Phase 3 studies (ELARIS UF-II) met primary efficacy endpoint and all ranked secondary endpoints
-
March 05, 2018- Endometriosis affects an estimated one in 10 women of reproductive age, but diagnosis can take up to six to 10 years(1,2)
-
February 26, 2018
-
February 21, 2018− First of two pivotal Phase 3 studies met primary efficacy endpoint and all ranked secondary endpoints
-
February 20, 2018Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau
-
February 17, 2018- At week 16, 37 and 51 percent of patients with plaque psoriasis treated with risankizumab achieved clear skin (sPGA 0) compared to STELARA® (ustekinumab) (14 and 25 percent)(1)
-
February 17, 2018- Upadacitinib showed a reduction in itch (pruritus) as early as Week 1(1)
-
February 16, 2018- Results from the 52-week CELEST study showed that many upadacitinib-treated patients who achieved clinical response§ after the study's 16-week induction phase maintained their response to treatment after the 36-week extension phase(1)
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
